Comparison
3 Methylglutaconic Aciduria Type 4 C1855126 vs 17q12 Recurrent Deletion Syndrome C6011081
Clinical comparison between 3 Methylglutaconic Aciduria Type 4 and 17q12 Recurrent Deletion Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 4 C1855126
A metabolic disorder affecting the nervous system that typically begins in childhood. Patients may experience movement difficulties, muscle stiffness, and developmental challenges. Care involves supportive therapies and symptom management.
17q12 Recurrent Deletion Syndrome C6011081
A genetic condition from deletion on chromosome 17. Can involve developmental delays, neurological features, and potential kidney involvement. Management requires regular monitoring and supportive therapies.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 4 C1855126
0-null
17q12 Recurrent Deletion Syndrome C6011081
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 4 C1855126
severe
17q12 Recurrent Deletion Syndrome C6011081
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 4 C1855126
Chronic
17q12 Recurrent Deletion Syndrome C6011081
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 4 C1855126
No
17q12 Recurrent Deletion Syndrome C6011081
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 4 C1855126
metabolic
17q12 Recurrent Deletion Syndrome C6011081
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type 4 C1855126
metabolic
17q12 Recurrent Deletion Syndrome C6011081
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-4-C1855126 and 17q12-recurrent-deletion-syndrome-C6011081 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 4 C1855126 | 17q12 Recurrent Deletion Syndrome C6011081 | Discriminating power |
|---|---|---|---|
| Movement and muscle tone | Movement difficulty and muscle stiffness are described; severity varies. | Neurologic features may occur, but stiffness is not specifically established. | Moderate |
| Development | Developmental challenges may begin in childhood. | Developmental delay is a recognized possible feature. | Low |
| Kidney involvement | Kidney disease is not established by the supplied description. | Potential kidney involvement warrants monitoring. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 4 C1855126 when
Childhood neurologic or developmental symptoms with suspected metabolic disease
The supplied profile emphasizes a metabolic nervous-system disorder.
Moderate
Abnormal organic-acid result needs disease context
An abnormal metabolite result is not itself a diagnosis and needs confirmation.
High
Severe progressive movement or tone problems
The left condition is categorized as severe, although course is variable.
Low
Choose 17q12 Recurrent Deletion Syndrome C6011081 when
Congenital developmental concerns with possible kidney findings
The right condition is a chromosomal deletion with potential renal involvement.
Moderate
Family or prenatal evaluation for a recurrent deletion
Genetic testing, not metabolic testing alone, addresses this etiology.
High
Moderate multisystem congenital presentation
Supplied severity is moderate, but individual outcomes vary.
Low
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 4 C1855126 | 17q12 Recurrent Deletion Syndrome C6011081 | Interpretation |
|---|---|---|---|
| Urine organic acids | May show elevated 3-methylglutaconic acid; cutoff not specified here. | No characteristic organic-acid pattern is established. | An abnormal result supports metabolic evaluation but does not alone diagnose type 4. |
| Chromosomal microarray or targeted deletion testing | Not the primary test suggested by the metabolic description. | Can identify a recurrent 17q12 deletion when present. | A confirmed deletion supports the right diagnosis; absence does not exclude other conditions. |
| Renal imaging or function monitoring | No specific renal abnormality is established here. | Monitoring is appropriate because kidney involvement may occur. | Findings guide surveillance; normal results do not exclude either condition. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 4 C1855126
- Outcome
- Often chronic and potentially severe, but individual outcome is not predictable from these data.
- Factors
- Neurologic severity, developmental needs, and response to supportive care.
17q12 Recurrent Deletion Syndrome C6011081
- Outcome
- Often chronic with moderate supplied severity and variable features.
- Factors
- Developmental, neurologic, and possible kidney involvement.
Time frame: Childhood onset is typical for the left; lifelong course may apply to both. Exact timelines are not established.
Confirmed diagnosis, organ involvement, and access to supportive services influence outlook.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Movement difficulty, stiffness, and developmental challenges may occur. Neurologic features and developmental delay may occur. Overlap is substantial; neither pattern is definitive. |
| Kidney complications | Not established from the supplied source. Potential kidney involvement requires regular monitoring. Renal risk is more specifically associated with the right condition. |
| Care burden | Supportive therapy and symptom management may be ongoing. Supportive care plus developmental and renal surveillance may be needed. Exact complication rates are not established here. |
Patient education highlights
- HighDiagnosis versus test result
An abnormal laboratory or genetic finding needs clinician confirmation and should not be self-interpreted.
- HighMonitoring
Report new movement, developmental, feeding, or urinary changes promptly; kidney checks may be relevant for 17q12 deletion.
- MediumSupportive care
Therapies are individualized. No treatment dose or cure is established by this comparison.